Chimerix Stock

Chimerix ROA

Delisted·Apr 17, 2025

The Return on Assets (ROA) of Chimerix (CMRX) as of Aug 26, 2026 is -60.54 %. In the previous year, Return on Assets (ROA) was -38.58 % — a change of 56.90% (lower).

ROA

-60.54 %

YoY

56.90%

Last updated:

In 2026, Chimerix's return on assets (ROA) was -60.54 %, a 56.90% increase from the -38.58 % ROA in the previous year.

The Chimerix ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2017
-30.18 USD
Jan 1, 2018
-36.43 USD
Jan 1, 2019
-145.46 USD
Jan 1, 2020
-49.72 USD
Jan 1, 2021
-254.42 USD
Jan 1, 2022
61.63 USD
Jan 1, 2023
-38.58 USD
Jan 1, 2024
-60.54 USD
The Chimerix ROA history
YEARROAYoY
-60.54 %+56.90%
-38.58 %-162.60%
61.63 %-124.22%
-254.42 %+411.69%
-49.72 %-65.82%
-145.46 %+299.32%
-36.43 %+20.72%
-30.18 %+13.28%
-26.64 %-19.21%
-32.97 %+62.25%
-20.32 %
Access this data via the Eulerpool API

Chimerix Stock analysis

What does Chimerix do? Chimerix Inc is a biopharmaceutical company focused on the development of antiviral drugs. The company was founded in 2002 and is headquartered in Durham, North Carolina. The history of Chimerix dates back to the research of Dr. George Painter, a renowned scientist in the field of antiviral therapy. He discovered that a certain group of molecules, known as nucleoside analogues, have antiviral properties. The idea was to use these molecules as a starting point for the development of drugs that specifically target viruses. The core idea of Chimerix was to create a new business model that is different from traditional pharmaceutical companies. Instead of focusing on the lengthy and costly development of new compounds, the company wanted to utilize existing molecules and create new drugs through targeted modifications. This approach was not only expected to be faster and cost-effective but also to offer higher chances of success. Chimerix is divided into several business segments. The most important segment is antiviral therapy, where the company focuses on developing drugs against various viruses such as Cytomegalovirus (CMV), Adenovirus, and Herpesvirus. Another business segment of Chimerix is oncology. Here, the company also relies on modifying existing compounds to develop new and effective cancer drugs. One promising molecule currently being developed is Brincidofovir, which not only has antiviral properties but also possesses antitumor properties. In addition to drug development, Chimerix also offers support for clinical trials. The company collaborates with various research institutions and biopharmaceutical companies to test the efficacy and safety of new compounds. The most well-known product of Chimerix is Brincidofovir. This antiviral drug is currently being tested in clinical trials and has the potential to be used against a range of viruses. Its use is particularly promising in patients undergoing immunosuppressive therapy, such as those after a stem cell transplant. Chimerix aims to develop innovative and effective drugs that help patients overcome serious diseases. With its unique business model and close collaboration with the research community, the company has already made promising progress and is an important player in the field of antiviral therapy and oncology. Chimerix is one of the most popular companies on Eulerpool.

ROA Details

Understanding Chimerix's Return on Assets (ROA)

Chimerix's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Chimerix's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Chimerix's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Chimerix’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Chimerix stock

Return on Assets (ROA) of Chimerix is -60.54 % in 2026.

Return on Assets (ROA) of Chimerix changed from -38.58 % to -60.54 %, representing a 56.90% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Chimerix since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Chimerix with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

Profitability — Chimerix

All Key Metrics — Chimerix